Oncoinvent ASA (ONCIN.OL) stock: Winston Score, insiders and Congress trades

Oncoinvent ASA is a Norwegian biotechnology company focused on developing treatments for cancer. Its lead product is Radspherin, a radioactive therapy designed to treat cancers that have spread to the lining of the abdomen — a condition called peritoneal carcinomatosis. The company targets patients with ovarian cancer and colorectal cancer, and its approach uses tiny radioactive particles injected directly into the abdominal cavity to kill cancer cells. Oncoinvent earns no meaningful revenue yet, as Radspherin is still in clinical trials. The company is based in Oslo, Norway, and is small, with a market cap of roughly $200 million. Its potential moat lies in the specialized nature of its technology and any intellectual property protecting its particle-based delivery method. The main risk is straightforward: if clinical trials fail to show that Radspherin is safe and effective, the company has no other product to fall back on, and it will need to keep raising money to fund ongoing research.